Digital pill

DEVICE3 trials

Sponsors

Brigham and Women's Hospital, University of Colorado, Denver

Conditions

Adherence, MedicationHIV InfectionsHIV/AIDSSubstance Use Disorders

Phase 3

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)

CompletedNCT03512418

Brigham and Women's HospitalHIV Infections, Substance Use Disorders

Start: 2019-06-20End: 2024-04-10Updated: 2025-09-17

Phase 4

Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use

CompletedNCT03842436

Brigham and Women's HospitalAdherence, Medication, HIV/AIDS, Substance Use Disorders

Start: 2018-10-01End: 2020-04-22Updated: 2022-12-22

Unknown Phase

Quantification of Tenofovir Alafenamide Adherence (QUANTI-TAF)

CompletedNCT04065347

University of Colorado, DenverAdherence, Medication, HIV/AIDS

Start: 2019-11-21End: 2023-05-16Updated: 2024-08-27

Related Papers

571. Effects of alcohol use on tenofovir alafenamide metabolites among persons with HIV: Implications from a pharmacokinetic model

Open Forum Infectious Diseases2026-01-01

Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine–Based Antiretroviral Therapy (QUANTI-TAF)

Clinical Infectious Diseases2024-04-187 citations

Real-World User Experiences with a Digital Pill System to Measure PrEP Adherence: Perspectives from MSM with Substance Use

AIDS and Behavior2022-01-2822 citations

Long-Term Stability of the Electronic Sensor Component of a Digital Pill System in Real-World Storage Settings

Journal of Pharmacy Technology2021-01-0610 citations